Get started
Author

Yufeng Xing

Observed names: Y. Xing, Yu-Feng Xing, Yu-feng Xing
ORCID: 0000-0001-6762-3788
Observed ORCID: 0000-0001-6762-3788
OpenAlex ID: A5007139780
Traditional Chinese medicine in the treatment of nonalcoholic steatohepatitis
2021 · Mingtai Chen, Ying Xie, et al. · Pharmacological Research · 83
ROS-responsive injectable hydrogels loaded with exosomes carrying miR-4500 reverse liver fibrosis
2024 · Huili Yang, Wanshun Wang, et al. · Biomaterials · 69
Chinese herbal formula ruangan granule enhances the efficacy of entecavir to reverse advanced liver fibrosis/early cirrhosis in patients with chronic HBV infection: A multicenter, randomized clinical trial
2023 · Yufeng Xing, Weichao Zhong, et al. · Pharmacological Research · 39
Astragaloside IV suppresses development of hepatocellular carcinoma by regulating miR-150-5p/β-catenin axis
2020 · Xiang Cui, Xiaoyan Jiang, et al. · Environmental Toxicology and Pharmacology · 38
Clinical and histopathological features of chronic hepatitis B virus infected patients with high HBV-DNA viral load and normal alanine aminotransferase level: A multicentre-based study in China
2018 · Yu-Feng Xing, Da-Qiao Zhou, et al. · PLoS ONE · 33
PDF
From gut to liver: unveiling the differences of intestinal microbiota in NAFL and NASH patients
2024 · Furong Huang, Bo Lyu, et al. · Frontiers in Microbiology · 23
A Non-invasive Model for Predicting Liver Inflammation in Chronic Hepatitis B Patients With Normal Serum Alanine Aminotransferase Levels
2021 · Xiaoke Li, Yufeng Xing, et al. · Frontiers in Medicine · 16
PDF
A classical herbal formula alleviates high-fat diet induced nonalcoholic steatohepatitis (NASH) via targeting mitophagy to rehabilitate dysfunctional mitochondria, validated by UPLC-HRMS identification combined with in vivo experiment
2023 · Mingtai Chen, Furong Huang, et al. · Biomedicine & Pharmacotherapy · 15
RETRACTED ARTICLE: Inhibition of TMEM16A suppresses growth and induces apoptosis in hepatocellular carcinoma
2020 · Chuantao Zhang, Jianxiang Liu, et al. · International Journal of Clinical Oncology · 13
Network Pharmacology and Molecular Docking Integrated with Molecular Dynamics Simulations Investigate the Pharmacological Mechanism of Yinchenhao Decoction in the Treatment of Non-alcoholic Fatty Liver Disease
2024 · Rong Yang, Dansheng Jiang, et al. · Current Computer - Aided Drug Design · 12
Shugan Xiaozhi Decoction Attenuates Nonalcoholic Steatohepatitis by Enhancing PPARα and L‐FABP Expressions in High‐Fat‐Fed Rats
2016 · Yu-feng Xing, Zhen Zhang, et al. · Evidence-based Complementary and Alternative Medicine · 10
PDF
Efficacy and Safety of a Chinese Herbal Formula (Invigorating Kidney and Strengthening Spleen) in Chronic Hepatitis B Virus Carrier: Results from a Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial
2013 · Jinsong He, Daqiao Zhou, et al. · Evidence-based Complementary and Alternative Medicine · 10
PDF
Identification of Potential TMPRSS2 Inhibitors for COVID-19 Treatment in Chinese Medicine by Computational Approaches and Surface Plasmon Resonance Technology
2023 · Rong Yang, Linhua Liu, et al. · Journal of Chemical Information and Modeling · 9
The deficiency of FKBP-5 inhibited hepatocellular progression by increasing the infiltration of distinct immune cells and inhibiting obesity-associated gut microbial metabolite
2021 · Chuantao Zhang, Xiang Cui, et al. · Journal of Gastrointestinal Oncology · 9
PDF
Efficacy of a Chinese herbal formula on hepatitis B e antigen-positive chronic hepatitis B patients
2020 · Yu-Feng Xing, Chun-Shan Wei, et al. · World Journal of Gastroenterology · 9
Intervention of Shugan Xiaozhi Decoction on Nonalcoholic Fatty Liver Disease via Mediating Gut‐Liver Axis
2022 · Huili Yang, Lian Feng, et al. · BioMed Research International · 8
PDF
[Preneoplastic markers of hepatitis B virus-associated hepatocellular carcinoma and their significance in clinical settings].
2007 · Guang-Dong Tong, Da-Qiao Zhou, et al. · PubMed · 3
Identification of pseudo-immune tolerance for chronic hepatitis B patients: Development and validation of a non-invasive prediction model
2023 · Shuo Li, Zhiguo Li, et al. · Frontiers in Public Health · 2
PDF
Efficacy and safety of acetyl-CoA carboxylase (ACC) inhibitors in the treatment of nonalcoholic steatohepatitis (NASH): A protocol for systematic review
2022 · Liubin Xu, Huili Yang, et al. · Medicine · 2
Joint association of inflammatory markers and sedentary time with mortality in metabolic dysfunction-associated steatotic liver disease population and the mediating role of inflammation
2025 · Liu-Bin Xu, Xin-Yu Hu, et al. · European journal of medical research · 1
PDF
Inferior mesenteric arteriovenous fistula: Progress in diagnosis and management
2025 · Congcong Shi, Lihong Chen, et al. · Medicine · 1
Case report: A large gastric calcifying fibrous tumor treated with endoscopic submucosal excavation
2024 · Ziyou Zhong, Zhenguo Li, et al. · Frontiers in Oncology · 1
PDF
Association of reduced renal function with different phase of chronic hepatitis B virus infection
2022 · Guangdong Tong, Weichao Zhong, et al. · Gut Microbiota and Integrative Wellness · 1
PDF
[Clinical outcomes of long-term anti-inflammatory and hepatoprotective treatments in patients with chronic hepatitis B].
2011 · Guang-dong Tong, Si-nuan Chen, et al. · PubMed · 1
TRIM21 Alleviates Alcoholic Liver Fibrosis by Inhibiting Ferroptosis Through Regulation of IDO1 Ubiquitination
2026 · Weichao Zhong, Lidan Luo, et al. · The FASEB Journal
Works count: 37
Citation count: 408
H-index: 10
I10-index: 12
Year
Topic
Type